Currently, the EGFR-TKI osimertinib is used as the standard first-line treatment for EGFR-mutant NSCLC in clinical practice and, recently, the KRAS-G12C inhibitor sotorasib has been approved worldwide as second-line treatment for KRAS-G12C mutant NSCLC [18,19]. Here, KRAS is linked to non-small cell lung carcinoma.